Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Gilead Sciences, Inc. shares valued at $368,790 were purchased by GILEAD SCIENCES, INC. on Apr 02 ’24. At $0.76 per share, GILEAD SCIENCES, INC. acquired 485,250 shares. The insider’s holdings grew to 7,345,473 shares worth approximately $505.59 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Parsey Merdad sold 2,000 shares, netting a total of over 145,920 in proceeds. Following the sale of shares at $72.96 each, the insider now holds 96,304 shares.
Before that, Parsey Merdad had sold 8,230 shares from its account. In a trade valued at $598,624, the Chief Medical Officer traded Gilead Sciences, Inc. shares for $72.74 each. Upon closing the transaction, the insider’s holdings decreased to 8,230 shares, worth approximately $6.38 million.
As published in a research note from Maxim Group on May 01, 2024, Gilead Sciences, Inc. [GILD] has been retained to a Buy and the price target has been revised to $85. Analysts at HSBC Securities upgraded the stock from ‘”a Reduce”‘ to ‘”a Hold”‘ outlook in a report released in late April. As of February 22, 2024, Truist has decreased its “Buy” rating to a “Hold” for GILD. Earlier on November 09, 2023, Deutsche Bank initiated its rating. Their recommendation was “a Hold” for GILD stock.
Analyzing GILD Stock Performance
During the last five days, there has been a surge of approximately 0.50%. Over the course of the year, Gilead Sciences, Inc. shares have dropped approximately -15.04%. Shares of the company reached a 52-week high of $87.86 on 01/19/24 and a 52-week low of $62.07 on 05/31/24. A 50-day SMA is recorded $66.03, while a 200-day SMA reached $73.95. Nevertheless, trading volume fell to 7.17 million shares from 5.8 million shares the previous day.
Support And Resistance Levels for Gilead Sciences, Inc. (GILD)
According to the 24-hour chart, there is a support level at 68.37, which, if violated, would cause prices to drop to 67.91. In the upper region, resistance lies at 69.44. The next price resistance is at 70.05. RSI (Relative Strength Index) is 58.60 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.62, which suggests the price will increase in the coming days. Percent R is at 35.28%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
